

Applicants: Ron S. Israeli, et al.

Serial No.: 10/751,346

Filed: January 2, 2004

Page 2

Listing of Claims

1-20. (Canceled)

21. (Currently Amended) A method of ablating, or killing, or eliminating normal, benign hyperplastic, and cancerous prostate epithelial cells comprising: providing a biological agent an antibody which binds to an outer membrane domain of prostate specific membrane antigen and contacting said cells with the biological agent antibody under conditions effective to permit both binding of the biological agent antibody to the outer membrane domain of the prostate specific membrane antigen and ablating, or killing, or eliminating of said cells.

22. (Canceled).

23. (Currently Amended) A method according to claim 21, wherein said contacting is carried out in a living mammal and comprises[:] administering the biological agent antibody to the mammal under conditions effective to permit both binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen and killing of said cells.

24. (Previously presented) A method according to claim 23, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or intramuscularly.

Applicants: Ron S. Israeli, et al.

Serial No.: 10/751,346

Filed: January 2, 2004

Page 3

25. (Currently Amended) A method according to claim 22, 21, wherein the an antibody is used in carrying out said method, the antibody being selected from the group consisting of a monoclonal antibody and a polyclonal antibody.
26. (Canceled).
27. (Currently Amended) A method according to claim 21, wherein the biological agent antibody is bound to a substance effective to kill, or ablate or eliminate said cells upon binding of the biological agent antibody to the outer membrane domain of the prostate specific membrane antigen of said cells.
28. (Previously presented) A method according to claim 27, wherein the substance effective to kill said cells is a cytotoxic agent.
29. (Previously presented) A method according to claim 28, wherein the cytotoxic agent is selected from the group consisting of a drug, a toxin, a radioactive substance, a chemotherapeutic, an enzyme and molecules of fungal, viral and bacterial origin.
30. (Currently Amended) A method according to claim 21, wherein the biological agent antibody is in a composition further comprising a physiologically acceptable carrier, diluent, or stabilizer.

Applicants: Ron S. Israeli, et al.

Serial No.: 10/751,346

Filed: January 2, 2004

Page 4

31. (Currently Amended) A method according to claim 21,
wherein the ~~biological agent~~ antibody is in a
composition further comprising a pharmaceutically
acceptable carrier, diluent, or stabilizer.

32 to 58. (Canceled)